Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance

Increasing levels of paediatric community‐acquired pneumonia (CAP), caused by drug‐resistant bacteria and antimicrobial resistance, vary with age and countries and, in some cases, serotypes. When empirical first‐line treatment administration fails, paediatricians should consider second‐line treatments based on the prevalence of local resistance. A more judicious use of antimicrobial agents is also required. Conclusion Knowledge of local epidemiology and an appropriate use of antimicrobial drugs are necessary to treat CAP in this era of antimicrobial resistance.